Technology evaluation: HYB-2055, Hybridon

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 4, 2005, Pages 376-383

  Switaj, Tomasz ^a   Lasek, Witold ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTINEOPLASTIC AGENT; CANCER VACCINE; DNA; DOCETAXEL; DOXORUBICIN; GEMCITABINE; HYB 2055; IMMUNOMODULATING AGENT; IMOXINE; INTERLEUKIN 12; INTERLEUKIN 6; IRINOTECAN; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; PACLITAXEL; PLACEBO; RIBOMUNYL; RITUXIMAB; TOLL LIKE RECEPTOR 9; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLERGIC ASTHMA; ALLERGIC DISEASE; ANEMIA; ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; BREAST CANCER; CANCER THERAPY; CHILL; CLINICAL TRIAL; COLON CANCER; CPG ISLAND; DISEASE EXACERBATION; DOSE RESPONSE; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DYSPNEA; ERYTHEMA; FATIGUE; FEVER; GLIOBLASTOMA; HUMAN; HYPOXIA; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INJECTION SITE REACTION; KIDNEY CARCINOMA; LIVER DYSFUNCTION; LUNG CANCER; LYMPHADENOPATHY; MELANOMA; MYALGIA; NAUSEA; NONHUMAN; PATENT; PROSTATE CANCER; REVIEW; RIGOR; SKIN INDURATION; SOLID TUMOR; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; VOMITING;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COMMUNICABLE DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOLOGIC FACTORS; INJECTIONS; MICE; NEOPLASMS; OLIGONUCLEOTIDES;

EID: 23344433384     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. 219076 Hybridon signs research collaborations with leading medical institutions in Paris and Oslo to develop antisense therapies for asthma and cancer. Hybridon Inc PRESS RELEASE 1996 September 09
2. 449162 Towards optimal design of second-generation immunomodulatory oligonucleotides. Kandimalla ER, Yu D, Agrawal S CURR OPIN MOL THER 2002 4 2 122-129
3. 465215 Hybridon's DNA molecules are potent immunomodulators. Hybridon Inc PRESS RELEASE 2002 September 26
4. 481040 Presentation given by Hybridon at the BIO CEO & Investor conference in New York. Hybridon Inc COMPANY PRESENTATION 2003 February 27
5. 481557 Hybridon shows activity of IMOs in allergic asthma. Hybridon Inc PRESS RELEASE 2003 March 11
6. 484673 HYB-2055 to enter cancer trials. Hybridon Inc COMPANY COMMUNICATION 2003 April 04
7. 485278 Novel synthetic immunomodulatory oligonucleotides (IMO): Antitumor activity, chemosensitization, and pharmacokinetics. Wang H, Dubuisson J, Huang P, Kandimalla ER, Yu D, Agrawal S, Zhang R PROC AM ASSOC CANCER RES 2003 44 Abs 2838
8. 490212 Hybridon's immunomodulatory agent enters the clinic. Hybridon Inc PRESS RELEASE 2003 May 19
9. 493652 CpG motifs in bacterial DNA and their immune effects. Krieg AM ANNU REV IMMUNOL 2002 20 709-760
10. 493654 CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. Segal BM, Chang JT, Shevach EM J IMMUNOL 2000 164 11 5683-5688
11. 496379 The Immune Response Corporation evaluates a second-generation HIV vaccine candidate incorporating Hybridon's immunomodulatory oligonucleotide technology. Immune Response Corp PRESS RELEASE 2003 July 09
12. 497303 Hybridon presents preclinical data showing immunological and antitumor activity of novel synthetic immunomodulatory oligonucleotides. Hybridon Inc PRESS RELEASE 2003 July 15
13. 497998 Immunomodulatory oligodeoxynucleotides containing CpG and synthetic YpG, CpR, and YpR motifs induce strong innate immune responses and mediate potent antitumor activity in nude mice bearing tumor xenografts. Kandimalla ER, Yu D, Bhagat L, Tang J, Wang H, Zhang R, Yang M, Wang J, Hoffman RM, Agrawal S PROC AM ASSOC CANCER RES 2003 44 Abs 6462
14. 504597 Hybridon's second-generation immunomodulatory oligonucleotides prevent development of allergic asthma in mouse models in preclinical studies. Hybridon Inc PRESS RELEASE 2003 September 11
15. 508192 Immune Response licenses Amplivax for HIV vaccine development. Immune Response Corp PRESS RELEASE 2003 October 09
16. 510112 World Allergy Organization - XVIII ICACI (Part I), Vancouver, Canada. Iddb author IDDB MEETING REPORT 2003 September 07-12
17. 511707 Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Cong YP, Song SS, Bhagat L, Pandey RK, Yu D, Kandimalla ER, Agrawal S BIOCHEM BIOPHYS RES COMMUN 2003 310 4 1133-1139
18. 515022 Medicinal chemistry and therapeutic potential of CpG DNA. Agrawal S, Kandimalla ER TRENDS MOL MED 2002 8 3 114-121
19. 515312 A phase I placebo-controlled study in volunteers of escalating doses of HYB2055, a second-generation immunomodulatory agent based on CpG DNA. Martin R, Sullivan T, Bhagat L, Kandimalla E, Wang D, Zhao Q, Burton C, Bryson P, Ng T, Binney S, Handy L, Agrawal S CLIN CANCER RES 2003 9 16 Suppl 1 Abs C100
20. 515313 HYB-2055, a novel immunomodulatory oligonucleotide induces potent innate and adaptive immune responses and shows broad spectrum antitumor activity in murine syngeneic tumor models. Wang D, Li Y, Yu D, Kandimalla ER, Agrawal S CLIN CANCER RES 2003 9 16 Suppl 1 Abs C101
21. 515314 A phase I study of a second-generation immunomodulatory oligonucleotide (HYB2055) in patients with advanced solid malignancies. Hwang JJ, Martin R, Fox-Sinclair ES, Bahrani A, Sullivan T, Park S, Agrawal S, Burns T, Waxdal M, Marshall JL CLIN CANCER RES 2003 9 16 Suppl 1 Abs C111
22. 515315 Preclinical antitumor evaluation of a second-generation immunomodulatory oligonucleotide (IMO), HYB2055, alone and in combination with taxotere and gemcitabine. Wang H, Huang P, Kandimalla ER, Yu D, Agrawal S, Zhang R CLIN CANCER RES 2003 9 16 Suppl 1 Abs C115
23. 515808 A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, Wang D, Tang JX, Tang JY, Knetter CF, Lien E, Agrawal S PROC NATL ACAD SCI USA 2003 100 24 14303-14308
24. 528469 Hybridon second-generation IMO's show potential for asthma. Hybridon Inc PRESS RELEASE 2004 March 23
25. 529604 Hybridon presents preclinical data demonstrating 2nd-generation immunomodulatory oligonucleotides inhibit tumor growth alone and in combination with Herceptin and Rituxan. Hybridon Inc PRESS RELEASE 2004 March 30
26. 529909 Hybridon successfully completes phase I healthy volunteer trial of HYB2055, its lead 2nd-generation immunomodulatory oligonucleotide. Hybridon Inc PRESS RELEASE 2004 March 31
27. 530551 Immunological activity of HYB2055, a TLR-9 agonist, in healthy volunteers. Sullivan T, Bhagat L, Kandimalla E, Martin R, Wang D, Zhao Q, Handy L, Binney S, Burton C, Bryson P, Ng T, Agrawal S PROC AM ASSOC CANCER RES 2004 45 Abs 4707
28. 537525 Hybridon's immunomodulatory candidate produces immune response. Hybridon Inc PRESS RELEASE 2004 May 10
29. 545444 A phase I study of HYB2055 in patients (pts) with advanced solid malignancies. Hwang JJ, Park S, Amin A, Martin RR, Sullivan T, Burns T, Agrawal S, Waxdal MJ, Malik S, Marshall JL PROC AM SOC CLIN ONCOL 2004 23 Abs 3111
30. 550358 Hybridon's immunomodulatory oligonucleotides show promise. Hybridon Inc PRESS RELEASE 2004 July 22
31. 566724 Hybridon begins phase II trial of anticancer drug. Hybridon Inc PRESS RELEASE 2004 October 26
32. 572029 Positive phase I results for Hybridon's anticancer oligo. Hybridon Inc PRESS RELEASE 2004 November 22
33. 572083 Modulation of toll-like receptor 9 responses through synthetic immunostimulatory motifs of DNA. Agrawal S, Kandimalla ER ANN NY ACAD SCI 2003 1002 30-42
34. 572095 Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Kandimalla ER, Bhagat L, Cong YP, Pandey RK, Yu D, Zhao Q, Agrawal S BIOCHEM BIOPHYS RES COMMUN 2003 306 4 948-953
35. 572106 Immunomodulatory oligonucleotides containing CpR and RpG dinucleotide motifs augment long-term immune responses to HBsAg. Li Y, Fugang Z, Kandimalla E, Agrawal S FASEB J 2004 18 4-5 Abs 558.14
36. 572108 Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Agrawal DK, Edwan J, Kandimalla ER, Yu D, Bhagat L, Wang D, Agrawal S INT IMMUNOPHARMACOL 2004 18 4-5 Abs 558.14
37. 572135 Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. Zhu FG, Kandimalla ER, Yu D, Tang JX, Agrawal S INTERNATIONAL IMMUNOPHARMACOLOGY 2004 4 7 851-862
38. 572386 Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S INT J ONCOL 2004 24 4 901-908
39. 588111 Hybridon's TLR-9 agonist shows preclinical promise. Hybridon Inc PRESS RELEASE 2005 March 03
40. 593748 A second-generation immunomodulatory oligonucleotide agonist of TLR9 shows antitumor activity and enhances effects of chemotherapy, radiation and antibody therapy in vitro and in vivo. Wang H, Rayburn E, Zhang Z, Wang Y, Li M, Kandimalla ER, Yu D, Agrawal S, Zhang R PROC AM ASSOC CANCER RES 2005 46 Abs 720
41. 601414 Hybridon announces oral presentation of results for phase I trial of IMOxine at ASCO 2005. Hybridon Inc PRESS RELEASE 2005 May 16
42. 603439 Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. Moore DJ, Hwang J, McGreivy J, Park S, Malik S, Martin RR, Sullivan TM, Agrawal S, Marshall J PROC AM SOC CLIN ONCOL 2005 24 Abs 2503
43. 606312 Use of CpG oligodeoxynucleotides as immune adjuvants. Klinman DM, Currie D, Gursel I, Verthelyi D IMMUNOL REV 2004 199 201-216
44. 606316 "Immunomers" - novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Yu D, Kandimalla ER, Bhagat L, Tang J-Y, Cong Y, Tang J, Agrawal S NUCLEIC ACID RES 2002 30 20 4460-4469
45. 606317 Potent CpG oligonucleotides containing phosphodiester linkages: In vitro and in vivo immunostimulatory properties. Yu D, Zhu F-G, Bhagat L, Wang H, Kandimalla ER, Zhang R, Agrawal S BIOCHEM BIOPHYS RES COMMUN 2002 297 1 83-90
46. 606319 Divergent synthetic nucleotide motif recognition pattern: Design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu F-G, Tang J, Wang H, Huang P, Zhang R, Agrawal S NUCLEIC ACID RES 2003 31 9 2393-2400
47. 606322 Role of CpG sequences in the induction of anti-DNA antibodies. Pisetsky DS, Wenk KS, Reich CF CLIN IMMUNOL 2001 100 2 157-163
48. 606337 Meta-analysis of published clinical trials of ribosomal vaccine (Ribomunyl) in prevention of respiratory infections. Boyle P, Bellanti JA, Robertson C BIODRUGS 2000 14 6 389-408
49. 611359 Company evaluation: Hybridon Inc. Zhou H RODMAN RENSHAW 2005 June 02